Mitsubishi UFJ Asset Management
CORT icon

Mitsubishi UFJ Asset Management’s Corcept Therapeutics CORT Stock Holding History

Mitsubishi UFJ Asset Management’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$27.2K Hold
313
– – ﹤0.01% 1261
2026
Q1 		$12.6K Hold
313
– – ﹤0.01% 1341
2025
Q4 		$12K Hold
313
– – ﹤0.01% 1333
2025
Q3 		$26K Hold
313
– – ﹤0.01% 1133
2025
Q2 		$23K Buy
+313
New +$22.7K ﹤0.01% 1156

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Mitsubishi UFJ Asset Management's CORT Position: Q2 2026 in Review

Mitsubishi UFJ Asset Management held its Corcept Therapeutics (CORT) position steady in Q2 2026 at 313 shares worth $27.2K. The position accounts for ﹤0.01% of the portfolio, ranked #1261.

Mitsubishi UFJ Asset Management first reported a position in CORT in Q2 2025 and has held it in 5 quarters since. 423 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • Mitsubishi UFJ Asset Management held 313 shares of Corcept Therapeutics worth $27.2K as of Q2 2026.
  • Mitsubishi UFJ Asset Management left its Corcept Therapeutics share count unchanged in Q2 2026.
  • Corcept Therapeutics made up ﹤0.01% of Mitsubishi UFJ Asset Management's portfolio in Q2 2026, its #1261 holding.
  • Mitsubishi UFJ Asset Management first reported a position in Corcept Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • 423 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Mitsubishi UFJ Asset Management's 13F filing for Q2 2026, filed 7 Aug 2026.